We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

KINAXO Launches Enhanced KinaTor™ Cellular Profiling Service
Product News

KINAXO Launches Enhanced KinaTor™ Cellular Profiling Service

KINAXO Launches Enhanced KinaTor™ Cellular Profiling Service
Product News

KINAXO Launches Enhanced KinaTor™ Cellular Profiling Service

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "KINAXO Launches Enhanced KinaTor™ Cellular Profiling Service"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KINAXO Biotechnologies has announced that it has added quantitative analysis to its KinaTor™ chemical proteomics platform tailored for the cellular profiling of kinase inhibitors.

The enhanced KinaTor™ Cellular Profiling Service enables KINAXO’s pharmaceutical and biotechnology clients to make informed decisions on which drug candidates to progress into advanced pre-clinical development.

The KinaTor™ Cellular Profiling Service platform may be employed in a number of further applications including target identification, drug reprofiling and drug rescue.

Commenting on the launch of the new service Dr Andreas Jenne KINAXO’s CEO said: "KINAXO is delighted to announce this significant development in the capabilities of our successful KinaTor™ platform. We look forward to putting the enhanced KinaTor™ Cellular Profiling Service to work for our existing and future clients."

KINAXO’s quantitative KinaTor™ Cellular Profiling Service utilizes proprietary chemical proteomics technologies combined with mass spectrometry to identify not only the drug candidate’s native molecular targets from cellular samples but also the affinities of these interactions. This data provides a valuable insight into the drug candidate’s in vivo molecular target profile.

The technology was developed by Dr Henrik Daub and Professor Axel Ullrich of the Max Planck Institute of Biochemistry in Martinsried and has been exclusively licensed by its technology transfer organization Max Planck Innovation to KINAXO Biotechnologies.

Commenting on the new service, Dr Klaus Godl KINAXO’s CSO said; "It is critically important that all biological interactions of a kinase inhibitor are evaluated, not just those with a subset of recombinant kinases. The new service will enable not only the identification of drug candidate interactions with proteins derived from real cellular samples but importantly also their affinities thus supporting more informed lead candidate selection."